Patents Assigned to Genentech
  • Publication number: 20180009894
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: July 24, 2017
    Publication date: January 11, 2018
    Applicant: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Patent number: 9862689
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I), wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: January 9, 2018
    Assignee: GENENTECH, INC.
    Inventors: Hans Iding, Reinhard Reents, Michelangelo Scalone, Francis Gosselin
  • Patent number: 9862778
    Abstract: Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding more than one target molecule or different epitopes on a single target molecule. The methods modulate parameters to improve assembly of the heteromultimeric proteins at higher yield and efficiency than otherwise possible. Also described are compositions comprising a hinge-containing polypeptide, such as a half-antibody.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: January 9, 2018
    Assignee: GENENTECH, INC.
    Inventors: Glen Giese, Amy Lim, Josefine Persson, Justin Scheer, Ambrose Williams
  • Publication number: 20180002344
    Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: June 15, 2017
    Publication date: January 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Jiangpeng Liao
  • Publication number: 20180000964
    Abstract: The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.
    Type: Application
    Filed: June 9, 2017
    Publication date: January 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Christine Tan, Ryan J. Watts, Joy Yu Zuchero, Xiaocheng Chen, Mark S. Dennis
  • Publication number: 20180000962
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: May 10, 2017
    Publication date: January 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Charles W. Eigenbrot, JR., Jagath Reddy Junutula, Henry Lowman, Helga E. Raab, Richard Vandlen
  • Publication number: 20180002433
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: June 5, 2017
    Publication date: January 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • Publication number: 20180000833
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 4, 2018
    Applicant: GENENTECH, INC.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • Patent number: 9855270
    Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 2, 2018
    Assignee: GENENTECH, INC.
    Inventors: Jeffrey J. Hager, James D. Joseph, Jing Qian, Nicholas D. Smith, Edna Chow Maneval, Debasish F. Roychowdhury, Lori Friedman, Deepak Sampath
  • Patent number: 9855269
    Abstract: The invention provides a method of inhibiting angiogenesis in a patient by administering a compound of formula (I): wherein R1 R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 2, 2018
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Terry Crawford, Seth F. Harris, Steven R. Magnuson, Chudi Nbdubaku, Lan Wang
  • Publication number: 20170369564
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: January 15, 2016
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • Publication number: 20170369510
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Snahel Patel, Terry Kellar, Malcolm Huestis, Daniel Shore, Michael Siu
  • Publication number: 20170369559
    Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patients for treatment with an anti-Abeta antibody. Methods include the use of prognostic and/or predictive biomarkers.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventor: Robert Graham
  • Publication number: 20170368039
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Application
    Filed: November 15, 2016
    Publication date: December 28, 2017
    Applicants: Forma TM, LLC, Genentech, Inc.
    Inventors: BAIR W. Kenneth, Timm R. BAUMEISTER, Alexandre J. BUCKMELTER, Karl H. CLODFELTER, Peter DRAGOVICH, Francis GOSSELIN, Bingsong HAN, Jian LIN, Dominic J. REYNOLDS, Bruce ROTH, Chase C. SMITH, Zhongguo WANG, Po-Wai YUEN, Xiaozhang ZHENG
  • Publication number: 20170370906
    Abstract: Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.
    Type: Application
    Filed: May 26, 2017
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Martine Darwish, Surinder Kaur, Dian Su, Keyang Xu
  • Patent number: 9850514
    Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: December 26, 2017
    Assignee: Genentech, Inc.
    Inventors: Michael W. Laird, Karthik Veeravalli
  • Patent number: 9850239
    Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: December 26, 2017
    Assignee: Genentech, Inc.
    Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Wendy Lee, Vickie Hsiao-Wei Tsui, Xiaojing Wang, Zhaoyang Wen
  • Publication number: 20170362339
    Abstract: The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.
    Type: Application
    Filed: November 18, 2015
    Publication date: December 21, 2017
    Applicants: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan WU, Eric Krauland, Michael Feldhaus
  • Publication number: 20170362228
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 21, 2017
    Applicant: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Zhiguo Liu, Tao Wang
  • Patent number: 9845291
    Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 19, 2017
    Assignee: Genentech, Inc.
    Inventors: Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Steven P. Govek, Mehmet Kahraman, Johnny Y. Nagasawa, Nicholas D. Smith, Simon Charles Goodacre, Nicholas Charles Ray